JWH-200

JWH-200

Systematic (IUPAC) name
(1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethanone
Clinical data
Legal status	AU: S9 (Prohibited) DE: Anlage II (Prohibited) US: Schedule I
Identifiers
CAS Number	103610-04-4 Y
PubChem	CID: 10045570
ChemSpider	8221134
Chemical data
Formula	C25H24N2O2
Molecular mass	384.469 g/mol
SMILES O=C(C1=CC=CC2=C1C=CC=C2)C3=CN(C4=C3C=CC=C4)CCN5CCOCC5
InChI InChI=1S/C25H24N2O2/c28-25(22-10-5-7-19-6-1-2-8-20(19)22)23-18-27(24-11-4-3-9-21(23)24)13-12-26-14-16-29-17-15-26/h1-11,18H,12-17H2 Key:SZWYXJHTNGJPKU-UHFFFAOYSA-N
(verify)

JWH-200 (WIN 55,225) is an analgesic chemical from the aminoalkylindole family that acts as a cannabinoid receptor agonist. Its binding affinity at the CB₁ receptor is 42nM, around the same as that of THC, but its analgesic potency in vivo was higher than that of other analogues with stronger CB₁ binding affinity in vitro, around 3 times that of THC but with less sedative effect, most likely reflecting favourable pharmacokinetic characteristics. It was discovered by, and named after, Dr. John W. Huffman.

Legal Status

Australia

JWH-200 is considered a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015). A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.

United States

The US DEA temporarily declared JWH-200 a schedule I controlled substance on 1 March 2011 through 76 FR 11075, and permanently instated the same schedule on 9 July 2012 in the Section 1152 of the Food and Drug Administration Safety and Innovation Act. As of 16 July 2015, the drug is a controlled substance in Canada.

See also

• JWH-018
• JWH-073
• CP-47,497
• HU-210
• A-796,260
• MEPIRAPIM
• WIN 55,212-2